UrgoStart® Plus Pad
UrgoStart® Plus Pad is an innovative, patented dressing developed by Urgo Medical composed of two exclusive technologies, TLC-NOSF Healing Matrix (NOSF* impregnated in a TLC Healing Matrix) and poly-absorbent fibres.
FEATURES AND CLINICAL BENEFITS
Treatment of chronic skin wounds with UrgoStart® Plus Pad promotes their healing.
Once in contact with wound exudate (fluid in the wound), the TLC-NOSF technology of UrgoStart® Plus Pad gelifies, which helps to:
- Limit the effect of the enzymes called matrix metalloproteinases (MMPs), excess of which in chronic wounds delays wound healing
- Maintain a moist environment necessary for wound healing
The polyacrylate fibres:
- Promote wound desloughing by trapping fibrin (yellowish slough on the wound bed).
- Help stop minor bleeding (haemostatic properties evaluated in vitro)
UrgoStart® Plus Pad:
- is suitable for covering also the periwound skin even when this skin is weakened
- is easy to apply
- is flexible (adapts to the body area to which it is applied) and comfortable
- is atraumatic for the wound and the periwound skin when it is removed
INDICATIONS
UrgoStart® Plus Pad is indicated for covering and treating the following skin wounds:
- Leg ulcers.
- Diabetic foot ulcers.
- Pressure ulcers (bedsores).
- Other long-lasting or recurrent wounds or wounds at risk of long lasting.
UrgoStart® Plus Pad is intended to be used for all healing phases: it is suitable for application to wounds covered with fibrin (yellowish slough on the wound bed) and to wounds with granulation tissue (red budding tissue on the wound).
For a highly exuding wound (that is, a wound with a high amount of fluid), UrgoStart® Plus Pad can be covered with an additional absorbent dressing.
UrgoStart® Plus Pad must be secured with a dressing securement system (for example, medical tape, flat, tubular mesh, or adhesive dressing)
CONTRAINDICATIONS
- Mucius membrane wounds.
- Malignant wounds.
- Fistula wounds.
- Epidermolysis bullosa wounds.
- Necrotic wounds (wounds covered with black dead tissue, eschars).
- Haemorrhagic wounds: UrgoStart® Plus Pad can be used to stop minor bleeding but should not be used as a surgical sponge.
- Known hypersensitivity of the patient to one of the TLC or TLC-NOSF dressings, or to carboxymethylcellulose (CMC).
PRECAUTIONS
In the event of signs or symptoms of infection before or after starting treatment with UrgoStart® Plus Pad, such as erythema (redness of the skin around the wound), oedema (swelling), heat or pain in the wound area, fever, enlargement of the wound, odour from the wound, or profuse exudate (that is, the large amount of fluid in the wound), consult a healthcare professional for appropriate treatment.
In the event of overgranulation (excessive raised formation of red budding tissue on the wound) before or after starting treatment with UrgoStart® Plus Pad, it must be reported to a healthcare professional for appropriate care.
Warnings
- Keep the pouches of UrgoStart® Plus Pad in their boxes until use (does not apply to large capacity packaging intended for hospitals).
- Do not use a previously used dressing.
- Discard all unused cut pieces of the dressing because the sterile condition is not maintained.
- Do not re-sterilize.
- Do not use beyond expiration date.
- The use of a dressing that is in non-sterile condition, re-sterilized, or beyond expiration date, does not guarantee performance of UrgoStart® Plus Pad and exposes the patient to the risk of infection.
CUTTING GUIDE


DIRECTIONS FOR USE

For Highly exudating wounds:

PRODUCT OPTIONS
| Product Code | Product Size | Units/Box |
|---|---|---|
| 100420 | 6x6cm | 10 |
| 100421 | 10x10cm | 10 |
| 100422 | 15x20cm | 10 |
Disclaimer: The product codes published on this website are local reference codes used for ordering, tender, and administrative purposes. They are not the manufacturer's product codes and may differ from the product codes shown on the product label or packaging. The product specifications and intended use remain unchanged.
